Transposon Therapeutics

Transposon Therapeutics is a clinical-stage biopharmaceutical company developing a novel therapeutic platform for neurodegenerative and aging-related diseases, including Alzheimer's disease. The company’s lead clinical compound, TPN-101, is the first-in-class LINE-1 reverse transcriptase inhibitor for treating neurodegenerative and autoimmune diseases. The company also possesses a discovery platform that supports the further development of novel therapies for other indications.